Group sales were +6% at constant exchange rates (CER)1, -2% when reported in CHF and +8% in USD2, in the first six months, driven by high demand for innovative medicines and diagnostics.Pharmaceuticals Division sales were +6% at CER, -1% when reported in CHF and +8% in USD, due to continued high growth in sales of our medicines across disease areas; Xolair (allergic asthma, chronic hives, food allergies), Hemlibra (haemophilia A), Ocrevus (multiple sclerosis), Phesgo (breast cancer) and Vabysmo (severe eye diseases) were the top growth drivers.Diagnostics Division sales were +3% at CER, -3% when reported in CHF and +6% in USD, driven by demand for immunodiagnostic and clinical chemistry products as well as pathology and molecular solutions.Core operating profit was +10% at CER, -1% when reported in CHF, driven by higher sales and other revenue; IFRS operating profit was -6% in CHF due to the appreciation of the Swiss franc.Core earnings per share were +9% at CER (-2% in CHF); IFRS diluted earnings per share were -8% in CHF due to the appreciation of the Swiss franc.Highlights:US Priority Reviews for giredestrant in an early-stage breast cancer, Enspryng in thyroid eye disease, Tecentriq in colon cancer as well as Gazyva\/Gazyvaro in idiopathic nephrotic syndrome and primary membranous nephropathy, two autoimmune diseases affecting the kidneysUS acceptance of a supplemental Biologics License Application for the Lunsumio and Polivy combination for blood cancer and Gazyva\/Gazyvaro for systemic lupus erythematosusPositive phase III data on divarasib in lung cancer; presentation of promising data on fenebrutinib in multiple sclerosis (phase III), Gazyva\/Gazyvaro in three autoimmune diseases (phase III) and enicepatide (CT-388) and petrelintide in obesity (phase II)Launch of Axelios 1, a transformative next-generation sequencing platform based on the innovative SBX technology, enabling the fastest DNA sequencing at scaleEU CE mark for two blood tests: Elecsys pTau217 to detect Alzheimer\u2019s pathology and Elecsys IGRA TB to identify latent tuberculosis infectionUS approval for Ventana PTEN (SP218) RxDx Assay, the first companion diagnostic to assess the levels of a key protein in prostate cancerGlobal collaboration agreement with Nurix Therapeutics for the BTK degrader bexobrutideg across malignant haematology, immunology and neurologyAgreement to acquire PathAI to transform AI-driven diagnosticsOutlook for 2026 confirmed.Outlook for 2026<\/p>\n
Roche (SIX: RO, ROP; OTCQX: RHHBY) expects an increase in Group sales in the mid single digit range (CER) for 2026. Core earnings per share are targeted to develop in the high single digit range (CER). Roche expects to further increase its dividend in Swiss francs.<\/p>\n
Key figuresCHF millions% changeJanuary-June20262025At CER1In CHFIn USDGroup sales30,36430,9446-28Pharmaceuticals Division23,62923,9856-18Diagnostics Division6,7356,9593-36Core operating profit11,85612,01010-1\u00a0Core EPS – diluted (CHF)10.8511.089-2\u00a0IFRS operating profit9,67110,3306-6\u00a0Roche CEO Thomas Schinecker: “Our strong momentum continued in the first half of the year, driven by a 6% sales increase at constant exchange rates and significant positive pipeline development.\u00a0\u00a0<\/p>\n
We reported positive phase III data for divarasib, reinforcing its potential as a best-in-class therapy in advanced lung cancer. Our regulatory momentum accelerated significantly as the US FDA granted five Priority Reviews: giredestrant in early-stage breast cancer, Enspryng in thyroid eye disease, Tecentriq in colon cancer and Gazyva\/Gazyvaro in two autoimmune kidney diseases.<\/p>\n
In Diagnostics, we reached major milestones with the launch of our transformative, highly cost-effective Axelios 1 sequencing solution, alongside EU CE mark for key diagnostic tests, including the Elecsys pTau217 blood test for Alzheimer\u2019s pathology and the Elecsys IGRA TB blood test, which delivers automated, scalable latent tuberculosis screening to laboratories worldwide.<\/p>\n
Get the latest news
\n
\n delivered to your inbox<\/p>\n
Sign up for The Manila Times newsletters<\/p>\n
By signing up with an email address, I acknowledge that I have read and agree to the Terms of Service<\/a> and Privacy Policy<\/a>.<\/p>\n Backed by our robust pipeline, we are well-positioned for sustained future growth. We confirm our outlook.\u201d<\/p>\n Group results<\/p>\n In the first six months of 2026, Roche sales were +6% at CER, -2% when reported in CHF, to CHF 30.4 billion due to strong demand for pharmaceutical products and diagnostic solutions. The appreciation of the Swiss franc against most currencies, notably the US dollar, had a significant impact on the results reported in Swiss francs compared to constant exchange rates.<\/p>\n Core operating profit was +10% at CER (-1% in CHF) to CHF 11.9 billion, driven by higher sales and other revenue. Core earnings per share were +9% at CER (-2% in CHF).<\/p>\n IFRS operating profit was -6% in CHF to CHF 9.7 billion. IFRS diluted earnings per share were -8% in CHF. The IFRS results were impacted by the appreciation of the Swiss franc.<\/p>\n Sales in the Pharmaceuticals Division were +6% at CER, -1% when reported in CHF, to CHF\u00a023.6\u00a0billion, with our medicines across disease areas continuing their strong growth.<\/p>\n The top five growth drivers – Xolair, Hemlibra, Ocrevus, Phesgo and Vabysmo – achieved total sales of CHF 11.0 billion, an increase of 12% at CER, or 4% in CHF, compared to the first six months of 2025.<\/p>\n Sales of products with expired patents (Avastin, Herceptin, MabThera\/Rituxan, Lucentis and Actemra\/RoActemra) were CHF 2.6 billion, a decrease of 8% at CER, or 15% in CHF, compared to the first six months of 2025.<\/p>\n In the United States, sales were +6% at CER, -3% when reported in CHF, due to continued growth of Xolair, Hemlibra, Polivy (blood cancer) and Tecentriq. This growth more than compensated for the lower sales of Perjeta (breast cancer) and Kadcyla (breast cancer) as well as the impact of biosimilar erosion on Actemra\/RoActemra (rheumatoid arthritis).<\/p>\n Sales in Europe were +1% at CER, or -1% when reported in CHF, as demand for Ocrevus, Evrysdi (spinal muscular atrophy) and Phesgo more than offset the impact of lower sales of Actemra\/RoActemra due to biosimilar competition and Perjeta because of the conversion of patients to Phesgo.<\/p>\n In Japan, sales were +11% at CER, -5% when reported in CHF, mainly due to product supply to third parties, as well as the uptake of Elevidys (Duchenne muscular dystrophy) and continued growth of Lunsumio (blood cancer), Vabysmo and Hemlibra.<\/p>\n Sales in the International region were +10% at CER, or +4% when reported in CHF, led by Phesgo, Vabysmo, Hemlibra, Ocrevus and Polivy. In China, sales were -9% at CER, or -12% when reported in CHF, due to the base effect of a severe flu season in 2025 on Xofluza sales.<\/p>\n The Diagnostics Division\u2019s sales were +3% at CER, -3% when reported in CHF, to CHF 6.7\u00a0billion, driven by growth in demand for immunodiagnostic and clinical chemistry products\u00a0 as well as pathology and molecular solutions. This growth more than offset the impact of healthcare pricing reforms in China.<\/p>\n Sales in the Europe, Middle East and Africa (EMEA) region were +3% at CER, -1% when reported in CHF, driven by higher sales of immunodiagnostic products, the clinical chemistry portfolio and molecular solutions.<\/p>\n In North America, sales were +8% at CER, -1% when reported in CHF, due to growth across the Core Lab and Pathology Lab customer areas.<\/p>\n Sales in Asia-Pacific were -5% at CER, or -12% when reported in CHF, mainly due to the healthcare pricing reforms in China, partially offset by growth in demand for clinical chemistry and immunodiagnostic products across the rest of the region.<\/p>\n In Latin America, sales were +10% at CER, or +5% when reported in CHF.<\/p>\n Pharmaceuticals: key developments<\/p>\n CompoundMilestoneRegulatoryGazyva\/Gazyvaro<\/p>\n Several autoimmune diseases<\/p>\n \u00a0<\/p>\n FDA grants Priority Review for Roche\u2019s Gazyva\/Gazyvaro for adults with primary membranous nephropathy (pMN)The Priority Review decision is based on results from the phase III MAJESTY study, where Gazyva\/Gazyvaro achieved significantly higher complete remission rates at two years compared to tacrolimus. If approved, Gazyva\/Gazyvaro will be the first FDA-approved therapy for pMN, following global approvals in lupus nephritis and ongoing regulatory filings in systemic lupus erythematosus and idiopathic nephrotic syndrome.pMN is a chronic autoimmune disease with no FDA- or EMA-approved therapies to date; when left untreated, up to 30% of patients progress to kidney failure over a period of 10 years. More information: Media Release<\/a>, 15 July 2026Enspryng<\/p>\n Thyroid eye disease<\/p>\n FDA grants Priority Review for Enspryng, the first and only at-home subcutaneous treatment option for thyroid eye disease (TED)The filing application is based on improvements seen across key efficacy endpoints from the global phase III SatraGO-1 and SatraGO-2 studies, including proptosis (bulging eyes) and diplopia (double vision) in active TED.Enspryng has the potential to become the first at-home subcutaneous disease-modifying standard of care for TED.TED is an autoimmune disease affecting approximately 155 out of every 100,000 people that can lead to facial disfigurement and vision-threatening complications if left untreated. More information: Media Release<\/a>, 30 June 2026Lunsumio and Polivy<\/p>\n Blood cancer<\/p>\n FDA accepts supplemental Biologics License Application for Lunsumio and Polivy combination for relapsed or refractory large B-cell lymphoma (LBCL)Filing acceptance is based on data from the phase III SUNMO study, where subcutaneous Lunsumio VELO plus Polivy demonstrated a 59% reduction in risk of disease progression or death.People with relapsed or refractory LBCL represent a population with one of the highest unmet needs in lymphoma and require timely access to effective therapies.If approved, this outpatient-ready regimen could enable access to care in the community setting, where most US patients receive treatment. More information: Media release<\/a>, 18 June 2026Tecentriq<\/p>\n Colon cancer<\/p>\n FDA grants Priority Review for Tecentriq for a certain type of stage III colon cancerFiling acceptance is based on data from the phase III Alliance ATOMIC study showing Tecentriq plus chemotherapy reduced recurrence or death risk by 50% versus chemotherapy alone.Nearly one in three patients with stage III colon cancer relapses within five years, highlighting a critical need for new adjuvant treatment options.If approved, Tecentriq plus chemotherapy could provide a new standard of care for the treatment of stage III dMMR\/MSI-H colon cancer after surgery. More information: Media Release<\/a>, 11 June 2026Giredestrant<\/p>\n Breast cancer<\/p>\n FDA accepts New Drug Application for giredestrant in ER-positive early-stage breast cancer, the first and only oral selective oestrogen receptor degrader with positive phase III results in the curative settingFiling acceptance, under Priority Review, is based on phase III data showing giredestrant reduced the risk of invasive disease recurrence or death by 30% compared with standard-of-care endocrine therapy.Giredestrant represents the first significant advance in adjuvant endocrine therapy in over 20 years.Giredestrant has the potential to become a new standard-of-care in the adjuvant setting; more than 90% of ER-positive breast cancer cases are diagnosed at an early stage (I\u2012III).The FDA has set a Prescription Drug User Fee Act date of 30 November 2026. More information: Media Release<\/a>, 2 June 2026Phase III, pivotal and other key read-outsDivarasib<\/p>\n Lung cancer<\/p>\n Divarasib shows superiority in head-to-head phase III trial against approved KRAS G12C inhibitors in non-small cell lung cancerPhase III (Krascendo 1) demonstrates best-in-class potential for patients with previously treated advanced KRAS G12C non-small cell lung cancer. Divarasib showed clinically meaningful improvements in progression-free survival compared to approved\u00a0 KRAS G12C inhibitors; no new safety signals were observed.Statistical significance for overall survival was achieved at the interim analysis in this poor-prognosis patient population. More information: Media Release<\/a>, 2 July 2026Fenebrutinib<\/p>\n Multiple sclerosis <\/p>\n Fenebrutinib significantly reduces relapses versus standard of care to approximately one every 17 years in relapsing multiple sclerosis (RMS)Late-breaking phase III FENhance 1 and 2 study results showed superiority of investigational fenebrutinib compared to teriflunomide in reducing relapses and brain lesions in RMS.Both studies showed positive trends in reducing disability progression with fenebrutinib compared to teriflunomide.Fenebrutinib could become a first-in-class BTK inhibitor and the first and only high-efficacy oral medication for both RMS and primary progressive multiple sclerosis (PPMS). More information: Media Release<\/a>, 22 April 2026OtherAlzheimer\u2019s integrated portfolio presentationRoche presents new data on Alzheimer\u2019s disease from across its integrated pharmaceuticals and diagnostics portfolio at AAICFive oral presentations in a featured research session highlighted trontinemab, including new long-term data from the phase Ib\/IIa Brainshuttle AD study and the design of phase III PrevenTRON study in preclinical Alzheimer\u2019s disease.New data on Roche\u2019s CE-marked Elecsys pTau217 blood test were presented on its use for the diagnosis of Alzheimer\u2019s disease in both primary and secondary care. More information: Media Release<\/a>, 7 July 2026Nurix Therapeutics collaborationRoche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg across malignant haematology, immunology and neurologyAgreement offers potential best-in-class targeted protein degrader therapy option for people living with B-cell malignancies.Collaboration adds to Roche\u2019s oncology pipeline and offers potential indications in immunology (chronic spontaneous urticaria) and neurology (multiple sclerosis).Bexobrutideg utilises a novel approach to eliminate the Bruton\u2019s tyrosine kinase (BTK) protein, potentially overcoming existing resistance mechanisms found with current standard-of-care BTK inhibitors. More information: Media Release<\/a>, 8 June 2026Obesity portfolio data presentationRoche presents new data advancing its obesity portfolio at the American Diabetes Association\u2019s 2026 scientific sessionsLate-breaking phase II data highlight enicepatide\u2019s (CT-388) efficacy and safety, reinforcing its potential to deliver best-in-class weight loss across a broad population of people living with overweight or obesity.Late-breaking data from the phase II ZUPREME-1 trial showcase petrelintide\u2019s efficacy, safety and compelling tolerability profile, which has the potential to redefine the weight management experience for people living with overweight or obesity.A phase II multi-arm trial evaluating enicepatide and petrelintide fixed-dose combinations will be initiated in the coming months to develop a differentiated treatment option. More information: Media Release<\/a>, 1 June 2026Oncology portfolio data presentationRoche presents new data at ASCO 2026, reinforcing giredestrant\u2019s potential to transform the treatment paradigm in early breast cancerNew data were presented from the lidERA study on giredestrant\u2019s potential as a new standard of care for adjuvant ER-positive breast cancer across all menopausal stages. Primary results were presented from the persevERA study on the numerical improvement in progression-free survival observed with first-line giredestrant plus palbociclib in advanced, endocrine-sensitive disease.Overall, Roche highlighted data on nine approved and investigational medicines – including bispecific antibodies, antibody-drug conjugates and brain-permeable molecules – that target urgent needs in breast, blood, lung and other cancers. More information: Media Release<\/a>, 19 May 2026Ophthalmology portfolio data presentationRoche presents extensive data showcasing its industry-leading ophthalmology portfolio at ARVO 2026New real-world data confirm the potent retinal drying of Vabysmo in neovascular or \u2018wet\u2019 age-related macular degeneration (nAMD) and diabetic macular edema (DME).Key data for Susvimo demonstrate its potential to provide lasting disease control through continuous delivery, while reducing treatment burden.Roche presented more than 45 abstracts at ARVO 2026, including 20 oral presentations across five retinal conditions. More information: Media Release<\/a>, 30 April 2026Pharmaceuticals salesSalesCHF millionsAs % of sales% changeJanuary-June2026202520262025At CERIn CHFPharmaceuticals Division23,62923,985100.0100.06-1United States12,22912,67051.852.86-3Europe4,5204,56619.119.01-1Japan1,3601,4255.85.911-5International5,5205,32423.322.3104 International: Asia-Pacific, CEETRIS (Central Eastern Europe, T\u00fcrkiye, Russia and Indian subcontinent), Latin America, Middle East, Africa, Canada, others\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Top 20 best-selling pharmaceuticalsTotalUnited StatesEuropeJapanInternationalCHF m%CHF m%CHF m%CHF m%CHF m%Ocrevus<\/p>\n Multiple sclerosis<\/p>\n 3,47072,300275810–41230Hemlibra<\/p>\n Haemophilia A<\/p>\n 2,492111,31395024171950626Vabysmo<\/p>\n Eye diseases (nAMD, DME, RVO)<\/p>\n 2,0598<\/p>\n","protected":false},"excerpt":{"rendered":"Group sales were +6% at constant exchange rates (CER)1, -2% when reported in CHF and +8% in USD2,…\n","protected":false},"author":2,"featured_media":107037,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[124],"tags":[17541,23165,1431,17545,18148,17543,52336,1203,3581,962,52333,35233,13355,6706,17866,9052,20611,626,52332,17542,2877,17546,14400,4004,17544,52334,134,8151,3743,52335,2679,41,28,1408],"class_list":["post-107036","post","type-post","status-publish","format-standard","has-post-thumbnail","category-roche","tag-ad","tag-23165","tag-1431","tag-17545","tag-18148","tag-announcement","tag-appreciation","tag-art","tag-at","tag-chf","tag-constant","tag-continues","tag-delivering","tag-due","tag-exchange","tag-first","tag-franc","tag-growth","tag-half","tag-hoc","tag-in","tag-lr","tag-momentum","tag-of","tag-pursuant","tag-rates","tag-roche","tag-roches","tag-sales","tag-significant","tag-strong","tag-swiss","tag-the","tag-to"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116968308210747517","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/107036","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=107036"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/107036\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/107037"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=107036"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=107036"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=107036"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}